Skip to content
Clinical Trials – home
EstoniaBack to Estonia

Clinical trials in Mustamae Linnaosa – page 8

159 clinical trials in Mustamae Linnaosa, Estonia. Every trial is listed in the EU Clinical Trials Register and updated daily.

EstoniaOur site in EstoniaKliinilisedUuringud.ee(opens in a new tab)
Mustamae Linnaosa at a glance
159
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

159 trials in Mustamae Linnaosa

Open in trial search

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:EstoniaEstonia
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Varicella

Not recruiting

Study on the Safety of a New Chickenpox Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children Aged 12-15 Months

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Study on Rosuvastatin and Atorvastatin for Preventing Heart Disease in Patients with High Genetic Risk

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Atorvastatin
  • Sponsor:University Of Tartu

Influenza

Not recruiting

Study on the Safety and Immune Response of aQIVc HD Vaccine Compared to a Drug Combination for Adults 50 Years and Older at Risk of Flu Complications

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/(H3N2)-LIKE VIRUS ANTIGEN
  • Sponsor:Seqirus UK Limited

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal oligosaccharide serotype 18C conjugated to CRM197
  • Sponsor:Sanofi Pasteur Inc.

Herpes zoster

Not recruiting

Study on Long-Term Effects and Safety of Herpes Zoster Vaccine with Recombinant Varicella Zoster Virus Glycoprotein E in Older Adults

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:GlaxoSmithKline Biologicals

Other cities in Estonia

The busiest research cities in the country

All 10 cities in Estonia

Clinical research in Mustamae Linnaosa

What the registry says about research in the country

01 Oncology Research

Clinical studies focusing on darolutamide treatment for cancer patients, alongside groundbreaking research in esophageal carcinoma treatment combining chemoradiotherapy with innovative therapeutic approaches.

  • Cancer Treatment Continuity
  • Esophageal Cancer Therapy
  • Treatment Safety Evaluation

These trials aim to advance cancer treatment options and improve patient outcomes through targeted therapies.

02 Infectious Diseases

Innovative research examining the effectiveness of ceftolozane/tazobactam in treating pediatric patients with nosocomial pneumonia, focusing on safety profiles and treatment responses.

  • Hospital-Acquired Pneumonia
  • Pediatric Treatment Solutions
  • Antibiotic Safety Studies

These studies aim to enhance treatment options for young patients with hospital-acquired infections.

03 Hematology & Rheumatology

Comprehensive research programs investigating treatments for Acute Lymphoblastic Leukaemia in young patients and evaluating upadacitinib for rheumatoid arthritis management.

  • Leukemia Treatment in Young Patients
  • Rheumatoid Arthritis Therapy
  • Immunotherapy Advances

These trials focus on improving survival rates and quality of life for patients with blood disorders and autoimmune conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.